SRF Q1 FY27 Earnings Call: Posts Record Rs.5,033 Cr Revenue, Guides 15-20% Chemicals Growth

CompoundingAI Research Published July 23, 2026 6 min read

SRF Ltd held its Q1 FY27 earnings call on July 22, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Quarterly Revenue and Profitability

Rs.5,033 Cr gross operating revenue — a record quarterly performance for SRF in Q1 FY 2026-2027, with all three business segments contributing.
EBITDA of Rs.1,116 Cr (+61% YoY) — margin stood at 22%; PAT of Rs.759 Cr (+76% YoY) reflected strong operational leverage and pricing tailwinds.
Chemicals business grew 26% YoY to Rs.2,315 Cr — driven by full capacity utilization (100%), robust domestic demand, and panic buying from customers seeking supply reliability.
Films & foils revenue surged 42% YoY to Rs.2,017 Cr — aided by temporary supply disruptions in the Middle East and strong overseas subsidiary performance.
Technical textiles contributed Rs.597 Cr — stable performance in nylon tire cord fabrics, with improved domestic demand and US export momentum in belting fabrics.
Interim dividend of Rs.5 per equity share — declared by the Board, reflecting confidence in the company's cash generation and outlook.

Performance chemicals grew 26% in Q1 FY 2026-2027 — management attributed the outperformance to uninterrupted operations, global sourcing (no domestic raw material reliance), and price improvements from panic buying.
Full-year chemicals growth guidance of 15-20% for FY 2026-2027 — management maintained the target, noting Q1 results position the company to deliver at the higher end of the range.
Refrigerant gas pricing remained strong in Q1 FY 2026-2027 — management expects pricing to sustain for the rest of FY 2026-2027, though Q2 and Q3 (India/Middle East) may see softer volumes while still delivering strong YoY growth versus Q2 FY 2025-2026.
Quota allocations through December 2026 — management cited this as a structural tailwind expected to drive further positive outcomes for the RefGas business.
Dahej facility has adequate space for 24 months — through at least FY 2026-2027 and into FY 2027-2028, supporting specialty chemicals expansion and ongoing CAPEX.
Middle East refrigerant volumes robust in Q1 FY 2026-2027 — strong YoY growth and sequential improvement versus Q4 FY 2025-2026, after earlier shipping disruptions were resolved via workarounds.

Aluminium foil margins improved from ~10% to 17% in Q1 FY 2026-2027 — management declined to specify a sustainable level for the rest of FY 2026-2027 but noted the export share reached ~half of volume, mostly to Europe.
Half of Q1 aluminium foil volume sold into Europe — if the trend holds through Q2 FY 2026-2027, the plant can reach full utilization; aseptic segment commissioning by Q1 FY 2027-2028 should improve domestic realizations.
Rs.520 Cr capex for electronics-grade capacitor and conductor films — capitalised in Q1 FY 26-27; capacitor film pricing is "significantly better" than vanilla packaging film, and full capacity utilization is targeted by Q1 or Q2 of FY 2027-2028.
Rs.250 Cr BOPET thick film line approved in India — 25,000 MTPA capacity with a 24-month commissioning timeline; part of a strategy to de-risk packaging films from polyester pricing volatility.
Packaging films EBIT margins expected above historical 8-12% range — management sees Q1 FY 2026-2027 as an aberration, with the structural uplift driven by overseas subsidiaries (Hungary, Alltech) and a shift to value-added products like capacitor films.
BOPET/BOPP correction expected in Q2 FY 2026-2027 — management expects no steep cliff, supported by crude oil staying in the ~$70/barrel range; Q1 saw disproportionate pricing due to the Middle East crisis.

6-7 new Active Ingredients ready for launch — management confirmed production capacity and chemistry are in place; the only remaining hurdle is registration and product launch timing by innovator customers, which remains uncertain.
Green shoots emerging in the agrochem space — management noted pricing pressure from China is abating and volume trends are improving, though the innovator world is expected to remain cautious in the near term before moving decisively on registrations.
PTFE value-added grades to reach meaningful scale around Q4 FY 2026-2027 and Q1 FY 2027-2028 — PVDF plant commissioning is slated for end of Q2 FY 2026-2027 (September 2026), with meaningful volumes likely by the start of FY 2027-2028.
Fluoropolymer portfolio (PTFE, PVDF, FP3, FP4) to see significant volumes towards end of FY 2027-2028 and early FY 2028-2029 — management expects "full capacity utilization during FY 2028-2029" as the long-dated ramp completes.
Kymos partnership timeline slipped by 3-4 months — due to design changes requested by Kymos for FP3/FP4 plants; the arrangement is an effective return on investment model, with the original December 2026 target pushed out.
Chemos contract revenue to begin soon after plant commissioning — management expects FY 2027-2028 to see lower revenue, with "full-stream revenue expected only in FY2028-2029".

Q2 FY 2026-2027 expected to be sequentially weaker than Q1 across all businesses — management guided that seasonality, especially in chemicals, will drive a lower Q2; films and foils performance is expected to stabilize at a higher baseline, while technical textiles Q2 is expected to improve YoY.
Chemicals H2 FY 2026-2027 likely to be stronger than H1 — management expects a slow, linear recovery in the base business, with the back half of the year delivering stronger performance as the recovery broadens.
Full-year chemicals growth guidance of 15-20% for FY 2026-2027 — Q1 results position the company at the higher end of this range, though management cautioned that the outperformance may not repeat each quarter.
Pharma business targets 20-30% of revenue by 2030 — management stated the "Pharma business has a stated goal to reach 20-30% of revenue by 2030"; progress is being made with a larger number of molecules and customers, though volumes remain small.
US anti-dumping duties on Chinese refrigerant imports — management sees no material impact for the rest of FY 2026-2027; Chinese pricing is expected to hold, and US shipments are unaffected.
Technical textiles Q1 FY 2026-2027 impacted by raw material price volatility — inability to renegotiate spreads should normalize in Q2 FY 2026-2027 and settle at levels better than the comparable period of FY 2025-2026; long-term contracts remain unchanged.

Technical textiles Q1 FY 2026-2027 impacted by raw material volatility — management expects Q2 FY 2026-2027 to normalize with spreads settling at levels better than FY 2025-2026; long-term contracts remain unchanged.
Electronics-grade capacitor film: early revenue from later part of Q2 FY 2026-2027 — full capacity utilization targeted by Q1 or Q2 of FY 2027-2028; the segment is expected to be less cyclical and accretive to overall film margins.
Aseptic packaging in testing stage with leading players — if successful, could open a new revenue segment in early FY 2027-2028, moving the business away from local-market pricing toward higher realizations.
Performance films long-term contracts with major FMCG customers unchanged — Q1 FY 2026-2027 saw additional panic buying from new and existing customers; management is avoiding predatory pricing because a correction is expected.
Odisha site strategic projects progressing as planned — next-gen refrigerants, backward integration, and specialty fluoropolymers are on track; post-commissioning of the new HFC-4 plant, SRF will be among the top three to four refrigerant gas manufacturers globally.